ONE-WAYOngoing theme · still written in the latest filings

CG009301: Chinese and U.S. IND Applications and Phase I Clinical Development

A development program for CG009301, a treatment for malignant hematologic cancers including leukemia, involving the filing of IND applications in China and the United States and the advancement of Phase I clinical trials.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2024-H1 →Still being written about.

Directionhelps1 helps · 0 hurts · 0 flat